NeuroScientific Biopharmaceuticals Limited (ASX:NSB)
Australia · Delayed Price · Currency is AUD 0.1400
+0.0050 (3.70%)
Jan 30, 2026, 4:10 PM AEST
NeuroScientific Biopharmaceuticals Company Description
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions.
Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders.
NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia.
NeuroScientific Biopharmaceuticals Limited
| Country | Australia |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Nathan Smith |
Contact Details
Address: 216 St Georges Terrace Perth, Washington 6000 Australia | |
| Phone | 61 8 6268 2641 |
| Website | neuroscientific.com |
Stock Details
| Ticker Symbol | NSB |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000012973 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Nathan Smith | Chief Executive Officer |
| Dr. Marian Sturm | Chief Scientific Officer |
| Dr. Catherine Cole | Chief Medical Officer |
| Christopher Bryan James Achurch B.Com., C.A. | Company Secretary |